Article Text

PDF
Response to: ‘Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?’ by Suyama and Okada
  1. Jun Won Park1,
  2. Jeffrey R Curtis2,
  3. Eun Bong Lee1
  1. 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
  2. 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
  1. Correspondence to Dr Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 110-744, Republic of Korea; leb7616{at}snu.ac.kr

Statistics from Altmetric.com

We deeply appreciate the comments by Suyama and Okada on our recent report regarding efficacy and safety of primary prophylaxis for pneumocystis pneumonia (PCP) using trimethoprim-sulfamethoxazole (TMP-SMX) in patients with rheumatic disease receiving prolonged, high-dose glucocorticoid treatment.1 2 They pointed out the possibility that patients with systemic lupus erythematosus (SLE) could have higher risk for adverse events related to TMP-SMX. They also indicated that discontinuation due …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles